Immunome (IMNM) vs SELLAS Life Sciences Group (SLS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
SELLAS Life Sciences Group (SLS) has outperformed Immunome (IMNM) over the past year, gaining 483.4% versus a gain of 37.8%. Over five years, SLS leads with a +27.5% price change compared with +9.7% for IMNM. SELLAS Life Sciences Group is the larger company by market cap ($2.35 billion vs $2.31 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMNM | SLS |
|---|---|---|
| Share price | $19.61 | $11.64 |
| Market cap | $2.31B | $2.35B |
| 1-day change | +1.55% | +3.37% |
| YTD return | -10.10% | +198.67% |
| 1-year return | +37.83% | +483.42% |
| 5-year return | +9.65% | +27.52% |
| EPS (TTM) | $-2.52 | $-0.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $6.94M | — |
| Revenue growth (YoY) | -23.23% | — |
| Net income (latest FY) | $-212.39M | $-26.86M |
| Operating margin | -3228.83% | — |
| Net margin | -3059.99% | — |
| 52-week high | $30.06 | $15.88 |
| 52-week low | $13.49 | $1.39 |
| Distance from 52-week high | -34.76% | -26.70% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +79.50% | +179.21% |
| Average volume | 1.20M | 6.52M |
| Shares outstanding | 118.00M | 201.95M |
| Employees | 247 | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLS has outperformed IMNM by 445.6 percentage points over the past year.
About Immunome
IMNM stock →Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 247 employees
About SELLAS Life Sciences Group
SLS stock →SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
IMNM vs SLS FAQ
Which is bigger, Immunome or SELLAS Life Sciences Group?
SELLAS Life Sciences Group (SLS) is larger, with a market capitalization of $2.35B compared with $2.31B for Immunome (IMNM).
Which stock has performed better over the past year, IMNM or SLS?
SLS returned +483.42% over the past 12 months, compared with +37.83% for IMNM (price return, excluding dividends). Past performance does not predict future results.
Are Immunome and SELLAS Life Sciences Group in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.